Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 151Breast Neoplasms 116Carcinoma, Non-Small-Cell Lung 65Triple Negative Breast Neoplasms 45Neoplasms 44Neoplasm Metastasis 44Lung Neoplasms 26Ovarian Neoplasms 25Squamous Cell Carcinoma of Head and Neck 24Stomach Neoplasms 22Melanoma 16Esophageal Neoplasms 16Adenocarcinoma 15Head and Neck Neoplasms 13Recurrence 12Esophageal Squamous Cell Carcinoma 12Cholangiocarcinoma 12Sarcoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Small Cell Lung Carcinoma 10Fallopian Tube Neoplasms 10Uterine Cervical Neoplasms 9Urinary Bladder Neoplasms 8Pancreatic Adenocarcinoma 8Colorectal Neoplasms 8Prostatic Neoplasms 7Inflammatory Breast Neoplasms 7Carcinoma, Pancreatic Ductal 7Breast Neoplasms, Male 7Biliary Tract Neoplasms 7

Interventions

Pemetrexed 9Nivolumab 8Cisplatin 8Carboplatin 8pembrolizumab 7130-nm albumin-bound paclitaxel 7Gemcitabine 6padeliporfin 5durvalumab 5Paclitaxel 5Bevacizumab 5palbociclib 4napabucasin 4atezolizumab 4Irinotecan 4Fulvestrant 4Fluorouracil 4Cyclophosphamide 4ribociclib 3osimertinib 3cobimetinib 3alectinib 3abemaciclib 3Trastuzumab 3Sunitinib 3Radiosurgery 3Drug Therapy 3Docetaxel 3Cetuximab 3Anastrozole 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Neoplasms by Site × Albumin-Bound Paclitaxel × Clear all
NCT02993731 2023-11-15

CanStem111P

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,134 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

NCT01964430 2023-06-28

apact

Celgene

Phase 3 Completed
866 enrolled 21 charts
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms, Neoplasms by Site, Pancreatic Diseases, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡